By Marcus Devlin
Two decades covering equity markets. Writes on single stocks, sectors, valuations and the trades behind the tape.
ASML Rewards Workers with €20,000 Bonus as AI Chip Boom Drives Profits
ASML, the Dutch chip equipment giant, is sharing its AI-fueled success with staff through a €20,000 one-time bonus and a long-term share awa
Wingstop Faces Gas Price Headwinds, But RBC Sees Recovery in Second Half
RBC Capital Markets expects Wingstop's Q2 same-store sales to drop 5.9% as high gas prices squeeze discretionary spending. However, the bank
Travelers Kicks Off Insurer Earnings Season with Strong Profit Beat
Travelers reported a strong second quarter, beating profit estimates as catastrophe losses declined and investment income climbed 13.6%. The
Five Warning Signs Flashing: Why I'm Adding a Simple Hedge to My Portfolio
Five warning signs—from inflation risks to euphoric investor positioning—are raising the odds of a sharper selloff. A simple, cash-neutral h
Commvault's Agentic AI and Identity Resilience Drive Subscriber Growth Above 20%
Oppenheimer forecasts Commvault's subscriber annual recurring revenue will rise more than 20% as demand for identity resilience products gro
PayPal, Perpetual, and Kakaku.com Show Why Takeover Deals Often Stall
A series of high-profile takeover bids, including a $53 billion approach for PayPal and a A$2.5 billion offer for Perpetual, are stalling ov
Apple and Nvidia in $4.9 Trillion Race as AI Trade Shifts to Services
Apple and Nvidia are neck-and-neck at around $4.90 trillion in market value. The AI trade is shifting from chip spending to services and upg
Botswana Weighs Right of First Refusal as Anglo American Picks De Beers Buyer
Anglo American has selected the Global Diamond Consortium as its preferred buyer for De Beers. Botswana, which already owns 15% of the diamo
IC Group Secures Exclusive Canadian Rights to Bullet Messaging Tech in Hybrid SaaS-Equity Deal
IC Group Holdings has locked in exclusive Canadian rights to Bullet Messaging's platform through a five-year software subscription. The deal
Wedbush: Zenas BioPharma Still Mispriced as Obexelimab's Safety Profile Overlooked
Wedbush says Zenas BioPharma remains mispriced because the market is fixated on the INDIGO trial's efficacy comparisons with Amgen's Uplizna
Canada's EV Sales Climb as US Market Slumps After Tax Credit Expiry
Canada's zero-emission vehicle sales are holding steady near 10% of new car sales, while the US market sees an 18% decline after federal tax
Telia Beats Q2 Profit Forecasts as Service Revenue Hits Four-Year High
Telia's second-quarter profit edged past analyst expectations as service revenue reached a four-year high and cost-cutting measures boosted